Form 8-K - Current report:
SEC Accession No. 0001104659-22-008977
Filing Date
2022-01-28
Accepted
2022-01-28 16:01:35
Documents
13
Period of Report
2022-01-25
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm224432d1_8k.htm   iXBRL 8-K 25804
2 EXHIBIT 3.1 tm224432d1_ex3-1.htm EX-3.1 57550
  Complete submission text file 0001104659-22-008977.txt   269207

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cldx-20220125.xsd EX-101.SCH 3066
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20220125_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20220125_pre.xml EX-101.PRE 22617
7 EXTRACTED XBRL INSTANCE DOCUMENT tm224432d1_8k_htm.xml XML 3631
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 22568704
SIC: 2835 In Vitro & In Vivo Diagnostic Substances